NAFLD / NASH as a Metabolic Disease: Improving Patients Outcomes – Part 2

Prof. A.G.(Onno) Holleboom, Netherlands, discusses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as a metabolic disease and reviews management strategies in order to improve patients outcomes.
73- A.G. (Onno) Holleboom Netherlands

Prof. A.G.(Onno) Holleboom, Netherlands, discusses the spectrum of NAFLD, where he presents a snapshot of the relative damages and repairs which focus on the NAFLD field in 2022. He then discusses the hepatic component metabolic syndrome (MetSy) and the mechanisms and pharmacological developments on NAFLD / NASH. For the clinicians he presents various statistics that summarise NAFLD / NASH as an ever more prevalent and severe liver disease.

Avatar photo

Prof. A.G.(Onno) Holleboom


Subscribe Our Newsletter To Get the Lastest Updates